Saratov JOURNAL of Medical and Scientific Research
Home

Experience of antiangiogenic and corticosteroid therapy of a diabetic macular edema

Year: 2017, volume 13 Issue: №2 Pages: 383-388
Heading: Ophtalmology Article type: Original article
Authors: Kamenskikh T.G., Batishcheva Yu.S., Kolbenev I.O., Tsipyashchyk A.F., Andreychenko O.A., Gileva E.M., Vasil'yeva T.V., Zakharova N.B.
Organization: Saratov State Medical University
Summary:

Diabetic macular edema (DME) is a leading cause of blindness in patients with diabetes. The purpose of the research is to evaluate the effectiveness of treatment of patients with DMOs resistant to the administration of ranibi-zumab, using the intrauritreal implant "Ozurdex". Material and Methods. 66 patients (98 eyes) are examined. All of the patients were divided, into three groups, depending on a stage of a diabetic retinopathy. The patients underwent a complex of examinations: along with traditional methods, optical coherence tomography, fluorescence angiography of the fundus, multifocal electroretinography, determination of the content of VEGF-Aand cytokines in serum were used. Results. According to ОСТ of a retina and a visometry there are differences in efficiency of treatment depending on a condition balance of cytokine. Conclusion. The use of the intrauretic implant "Ozurdex" was more effective in patients with DMO in the stage of p re-pro I iterative diabetic retinopathy and in patients resistant to anti-VEGF therapy.

Keywords: optical coherent tomography, intravitreal injections, diabetic macular edema, cytokines, corticosteroid therapy, antiangiogenic therapy

Bibliography:
1. Klein R, Klein BE, Moss SE, Cruickshank KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The longterm incidence of macular edema. Ophthalmology 1995; (1): 11-15
2. Laursen ML, MoellerF, Sander B, SjoelieAK Subthreshold micropulse diode laser treatment in diabetic macular oedema. Ophthalmology 2004; 1173-1179
3. Scholl S, Kirchhof J, Augustin AJ. Pathophysiology of macular edema. Ophthalmology 2010; (224): 8-15
4. BresnickGH. Diabetic Maculopathy. Ophthalmology 1983; (90): 1301-1317. doi: 10.1016/S0161-6420 (83) 34388-8
5. Балашевич Л. И. Измайлов А.С. Диабетическая офтальмопатия. СПб.: Человек, 2012; 36 с.
6. Rangasamy S, McGuire PG, Das A. Diabetic retinopathy and inflammation: Novel therapeutic targets. Middle East Afr J Ophthalmol 2012; 19 (1): 52-4103. doi: 10.4103/0974-9233.92116
7. Simo R, Carrasco E, Garcia-Ramirez M, Hernandez С Angiogenic and Antiangiogenic Factors in Proliferative Diabetic Retinopathy. Curr Diabetes Rev 2006; 2 (1): 71-98. doi: 10.2174/157339906775473671
8. Joussen AM, Smyth N, Niessen С Pathophysiology of diabetic macular edema. A.M. Dev Ophthalmol 2007; 39: 1-12. doi: 10.1159/000098495
9. Vujosevic S, Midena E. Retinal Layers Changes in Human Preclinical and Early Clinical Diabetic Retinopathy Support Early Retinal Neuronal and Muller Cells Alterations. Journal of Diabetes Research 2013; 90: 50-58. doi: 10.1155/2013/905058
10. Doga AV, Kachalina GF, Pedanova EK, Buryakov DA. Modern aspects of diagnosis and treatment of diabetic macular edema. Diabetes 2014; 4: 51-59
11. OlaM, Nawaz М, Khan H,AlhomidaA. Neurodegeneration and Neuroprotection in Diabetic Retinopathy. IJMS 2013; 14 (2): 2559-2572. doi: 10.3390/ijms14022559
12. Jain A, Varshney N, Smith С The Evolving Treatment Options for Diabetic Macular Edema. Int J Inflam 2013; 2013: 689276. doi: 10.1155/2013/689276
13. Villarroel M, Ciudin A, Hernandez C, Simo R. Neurodegeneration: An early event of diabetic retinopathy. WJD 2010; 1 (2): 57-64. doi: 10.4239/wjd.v1.i2.57
14. Barber AJ, Gardner TW, Abcouwer SF. The Significance of Vascular and Neural Apoptosis to the Pathology of Diabetic Retinopathy. Investigative Ophthalmology and Visual Science 2011; 52 (2): 1156-1163. doi: 10.1167/iovs.10-6293
15. Konenkov VI, Klimontov VV, Chernih VV, Tyan NV. Anti-VEGF drugs in the treatment of diabetic macular edema. Diabetes 2013; (4): 78-84
16. Haller JA, Bandello F, Belfort R. Jr, et al. OZURDEX GENEVA Study Group. Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Macular Edema Due to Retinal Vein Occlusion. Ophthalmology 2010: 34-46
17. Nehme A, Edelman J. Dexamethasone Inhibits High Glucose-, TNF-a.

AttachmentSize
2017_02-1_383-388.pdf2.1 MB
All articles of the authors: Zakharova N.B., Vasil'yeva T. V. , Tsipyaschuk A.F. , Kolbenev I.O., Kamenskikh T.G., Gileva E.V. , Batischeva Yu.S. , Andreychenko O.A.

No votes yet